Though Livmarli is witnessing continued demand and driving the top line, the company’s high dependence on the drug remains a concern. In the past year, shares of Mirum have surged 83.2% against ...

LIVMARLI is the first and only treatment available for cholestatic pruritus in patients with Alagille syndrome and ...

Mirum Pharmaceuticals, Inc. shows strong growth with a 43% revenue jump and promising pipeline assets. Click here for my ...

Shares of Mirum Pharmaceuticals, Inc. MIRM have rallied 90.9% in the past six months compared with the industry’s increase of just 1.1%. The company’s lead product is Livmarli (maralixibat ...

A replay of this webcast will be available for 30 days. About Mirum Pharmaceuticals LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults.

LIVMARLI is the first and only treatment available for cholestatic pruritus in patients with Alagille syndrome and Progressive Familial Intrahepatic Cholestasis in Japan “We are thrilled to see ...

and Welfare for LIVMARLI ® (maralixibat) oral solution for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC ...